INTRODUCTION
• Presence of epidermal growth factor receptor (EGFR) mutation defines a distinct subtype of non-small cell lung cancer (NSCLC) sensitive to EGFR tyrosine kinase inhibitors (TKIs). 1 Common activating mutations (Del19, L858R) account for ~90% of EGFR M+ NSCLC cases
• Reversible EGFR TKIs have shown improved progression-free survival (PFS), [2] [3] [4] [5] [6] [7] [8] [9] but no benefit in overall survival (OS) versus platinum-based chemotherapy in randomised trials [8] [9] [10] [11] [12] [13] [14] • In two pivotal studies, afatinib, an oral, irreversible ErbB family blocker, improved PFS and patient-reported outcomes (PRO) versus standard platinum-based chemotherapy in first-line EGFR M+ NSCLC 15, 16 -Afatinib also significantly prolonged OS in the EGFR Del19 mutation subgroup 17 
OBJECTIVES
• To date, no head-to-head trial results exist to compare afatinib, gefitinib or erlotinib in EGFR M+ NSCLC -Previous NMAs compared these treatments in the randomised population, but not by mutation type 18 • Based on the EGFR M+ study network requested as a sensitivity analysis by the National Institute for Health and Care Excellence (NICE) during its appraisal of afatinib (TA310), 19 a Bayesian NMA to estimate relative treatment effects of afatinib versus erlotinib and gefitinib for PFS and OS by mutation type (Del19 and L858R) was conducted
LIMITATIONS
• A number of assumptions had to be made in order to conduct the NMA -Sufficient clinical and methodological homogeneity of the clinical studies and the patient populations studied -Differences observed in the inclusion criteria and some of the patients' baseline characteristics across the included studies may have influenced the results
• The small number of studies included in this analysis may increase the uncertainty of the results compared with the published NMA originally submitted to NICE 18, 19 • These limitations should be taken into consideration when interpreting the results of the present analyses
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METHODS

RESULTS
• For PFS, the results of the NMA showed that afatinib has the highest expected probability of being the best treatment for NSCLC with common EGFR mutations (Del19/L858R combined; Table 1) -Afatinib also showed the highest probability of being the best treatment in the individual EGFR Del19 and L858R mutation subgroups
• A higher probability of being the best treatment was also shown with afatinib for OS in patients with common EGFR mutations, particularly in the Del19 subgroup. No difference was observed between the TKIs in the L858R subgroup ( 
Figure 1. Network of trials for PFS (A) and OS (B)
Statistical analysis
• The NMA was conducted using WinBUGS 1.4.3 20 • Hazard ratios (HRs) and probability of being the best treatment are reported for PFS and OS outcomes
• All baseline and intervention effect parameters were given flat (uninformative) normal density (0, 1,000) priors, and between-study standard deviation was given flat uniform distributions, with an appropriately large range given the scale of measurement
• A fixed-effects model was used (since there were instances with only one trial per comparison) and the model's fit was assessed by the overall residual deviance. Convergence was assessed by using the Brooks-Gelman-Rubin diagnostic in WinBUGS
• The results of all analyses were based on a sample of 50,000 simulations after a burn-in period of 20,000 simulations had been discarded • Based on the NMA, afatinib significantly improved PFS versus gefitinib and erlotinib in patients with common EGFR mutations (Table 2) • Results also favoured afatinib in the individual EGFR mutation subgroups (Del19 and L858R), although only the comparison of afatinib and gefitinib in the Del19 subgroup was statistically significant (Table 2) *Statistically significant Cr. Int., credible intervals; DIC, decision information criterion
• Based on the NMA, a trend favouring afatinib compared to gefitinib and erlotinib was observed for OS in patients with common EGFR mutations ( Figure 2) RESULTS (cont.) Figure 
OS in the EGFR Del19 mutation subgroup CONCLUSIONS
• Based on this NMA, considering the limitations described above, afatinib appears to provide improved clinical benefit compared to the reversible EGFR TKIs erlotinib and gefitinib as first-line treatment for EGFR M+ NSCLC
• In line with previous findings, 18 this NMA shows superiority of afatinib versus erlotinib and gefitinib in PFS in patients with common EGFR mutations (Del19 and L858R combined), as well as a clear trend towards superiority by each mutation subgroup -In addition to the findings of this NMA, in recent updated analyses of the LUX-Lung 3 and 6 trials, the superiority of afatinib over chemotherapy in PFS and PRO in EGFR M+ NSCLC was also confirmed 21 • For OS, afatinib showed a trend towards superiority in patients with common EGFR mutations, particularly the Del19 mutation; no difference in OS was shown between the TKIs in the L858R subgroup -These findings are consistent with recent analyses of the LUX-Lung 3 and 6 trials demonstrating significant OS improvement in patients with the Del19 mutation (but not L858R) 17 • Based on this NMA, afatinib appears to be the best treatment option for NSCLC with common EGFR mutations, particularly the Del19 mutation
• A direct trial-based comparison of the efficacy of these agents is warranted to clarify their relative benefits -A trial designed to evaluate the efficacy of afatinib versus gefitinib in NSCLC with common EGFR mutations is ongoing 22
Figure 2. OS common EGFR mutations (Del19/L858R combined)
*Results were reported for the combined EGFR M+ subgroup; † Results from the intent-to-treat population were used for the analysis, as differential activity based on individual EGFR mutation type was not reported Carb, carboplatin; Cis, cisplatin; Doc, docetaxel; Gem, gemcitabine; Pac, paclitaxel; Pem, pemetrexed
Trial selection for inclusion in NMA and assumptions
• All trials investigating gefitinib, erlotinib or afatinib in treatment-naïve EGFR M+ NSCLC were included -Results from the LUX-Lung 3 and 6 trials of afatinib in EGFR M+ NSCLC were used [15] [16] [17] -In the First Signal trial, PFS was reported for the EGFR M+ subgroup (including Del19 and L858R) 8 -In the WJTOG 3405 trial, OS based on EGFR mutation type was not reported, but it was stated that mutation type had no impact on the results. 12 Thus, the reported OS data was used for both mutation types in this NMA
• Based on these criteria, nine studies were included in the NMA: nine studies reported PFS and six reported OS by mutation type (Figure 1 )
Outcomes included in the NMA
• For all trials, PFS and OS were analysed for common EGFR mutations and by mutation type (Del19/L858R)
• PFS was reported by central independent review and/or investigator assessment
• Since the majority of studies included in the network reported only investigator-assessed PFS, this was used in the primary analysis
• The difference in OS between afatinib and gefitinib or erlotinib was even more pronounced in the EGFR Del19 mutation subgroup (Figure 3) International 
